Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.

Oncology research - 1 Jan 2023

Zhu Sha, Xu Nanwei, Liang Jiayu, Zhao Fengnian, Wang Zilin, Ni Yuchao, Dai Jindong, Zhao Jinge, Zhang Xingming, Chen Junru, Sun Guangxi, Shen Pengfei, Zeng Hao

Abstract excerpt

Background: KMT2 (lysine methyltransferase) family enzymes are epigenetic regulators that activate gene transcription. KMT2C is mainly involved in enhancer-associated H3K4me1, and is also one of the top mutated genes in cancer (6.6% in pan-cancer). Currently, the clinical significance of KMT2C mutations in prostate cancer is understudied. Methods: We included 221 prostate cancer patients diagnosed between 2014...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenesis, Genetic
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Mutation

Share to Prostate Cancer Treatment and Research

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 37415738
DOI: 10.32604/or.2023.028321
PMCID: PMC10319590

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.PMID 37415738Read ↗

KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.Semantic proximity Read ↗

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.Semantic proximity Read ↗

KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.Semantic proximity Read ↗

KMT2C is Potential Prognostic Biomarker and its Immune Regulating Roles in Pan-Cancer: A Comprehensive AnalysisSemantic proximity Read ↗

A Pan-Cancer Study of KMT2 Family as Therapeutic Targets in CancerSemantic proximity Read ↗

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumorsSemantic proximity Read ↗

Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.Semantic proximity Read ↗

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancersSemantic proximity Read ↗

Pan-Cancer Analysis of Histone Methyltransferase KMT2D with Potential Implications for Prognosis and Immunotherapy in Human CancerSemantic proximity Read ↗

Germline variants in early and late-onset Brazilian prostate cancer patients.Semantic proximity Read ↗

A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.Semantic proximity Read ↗

Bioinformatic determination of the expression and clinical value of the histone lysine demethylase family in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.